Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7383322 | 1.00 | AKR1C1 (0.65) | AKR1C1HPGDAKR1C3LCKFYN | |
| SCHEMBL11557846 | 0.85 | ALDH1A1 (0.59) | AKR1C1HPGDAKR1C3LCKFYN | |
| SCHEMBL11557849 | 0.85 | ALDH1A1 (0.59) | AKR1C1HPGDAKR1C3LCKFYN | |
| SCHEMBL7844079 | 0.82 | AKR1C3 (0.67) | AKR1C1AKR1C3LCKFYNDAO | |
| SCHEMBL7844082 | 0.82 | AKR1C3 (0.67) | AKR1C1AKR1C3LCKFYNDAO | |
| SCHEMBL28205425 | 0.81 | LCK (0.44) | AKR1C1HPGDLCKFYNDAO | |
| SCHEMBL8643666 | 0.80 | MEN1 (0.71) | AKR1C1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL8643668 | 0.80 | MEN1 (0.71) | AKR1C1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL7046304 | 0.79 | MEN1 (0.44) | AKR1C1AKR1C3LCKFYNDAO | |
| SCHEMBL7046303 | 0.79 | MEN1 (0.44) | AKR1C1AKR1C3LCKFYNDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4171366-A | 1-Naphthothienylalkyl-1H-imidazoles | CIBA-GEIGY CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | AKR1C1 1450/4885HPGD 974/4885AKR1C3 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.